Physician profile
Satish Patel
NPI 1629182704
$3,267.20
in general payments reported to CMS, 2019-2025
18 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $361 · 2021: $1,406 · 2022: $150 · 2023: $278 · 2024: $460 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,309.12 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $651.80 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $407.97 | 2023-2025 | |
| Medtronic, INC. | $146.67 | 2023 | Percept PC Brainsense |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.61 | 2019-2021 | |
| Vertiflex, INC. | $135.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $84.44 | 2021-2025 | Mounjaro, Zepbound |
| Conmed Corporation | $62.50 | 2023 | Airseal |
| Bsn Medical INC | $28.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.37 | 2022 | |
| Cycle Pharmaceuticals INC | $25.26 | 2025 | Tascenso Odt, Bafiertam |
| Heron Therapeutics, INC. | $23.52 | 2025 | Zynrelef |
| Allergan, INC. | $21.90 | 2020 | |
| Exact Sciences Corporation | $19.65 | 2025 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.79 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.53 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.